The OS for peptide therapy — with a research team’s intelligence and oversight behind every prescription
iksa is the harness for n‑of‑1 medicine. Peptide medicine is opening up fast, and clinics prescribing every kind of peptide can run trial-grade monitoring, evidence and adverse event reporting around each patient.
Each kind of peptide has its own science and its own checks, and your protocol sets them for each patient
Serious scientific interest is gathering behind these therapies, and some may prove lifesaving, which makes each patient on a protocol a trial of one worth running at full rigor. Clinics prescribe peptides across growth and body composition, metabolic health, recovery and repair, immune support, skin, sleep and sexual health, from approved drugs through compounded ones. A growth-axis protocol shows how deep the reading goes: the nearest written checks sit on the label of the one approved GHRH analogue, with glucose before the start and periodically after, IGF‑1 during, and stopping considered on a persistent elevation, and in its trials HbA1c reached 6.5% or more by week 26 in 5% on drug against 1% on placebo.
- On the dates your protocol setsEvery peptide protocol: Whatever the class, your program follows the compound you prescribed, the pharmacy and lot it came from, site and immune reactions, and the symptom or function you prescribed it for.
- Before every cycle, and once during itIGF‑1, on a growth-axis protocol: It falls with age and two assays can read the same blood differently, so you read it by age and sex on one assay, and his Z-score shows when a birthday or a new assay has moved the reading with nothing in him having changed. High in the range isn’t a goal, because mortality climbs at both ends of IGF‑1 in the cohorts and higher levels track with more prostate, colorectal and breast cancer. Above his age range the cycle waits for a repeat, and if it stays high with the protocol off, that’s an endocrine work-up.
- Within three months of every startFasting glucose and HbA1c, on the same protocol: In the nearest long trial, two years of an oral drug that raises growth hormone, not itself a peptide, in healthy adults over 60 (Annals of Internal Medicine, 2008), fasting glucose rose about 5 mg/dL and insulin sensitivity fell. HbA1c averages the recent weeks, so the fasting draw can show a shift first, and the prediabetes lines, 100 mg/dL or 5.7%, are where you weigh another cycle for this patient.
- Once a year, from a first value before Cycle 1PSA, for men on that protocol: The USPSTF leaves it to each man from 55 to 69 and recommends against it from 70, and the AUA would re-test every two to four years, so a yearly PSA is a rule you chose, and your note holds why: IGF‑1 tracks modestly with overall and aggressive prostate cancer. The 4.0 a lab prints runs high for his decade, which reads nearer 3.5, and what you’d hold for is a rise on his line that repeats.
- On each screening’s own interval, by age and historyAge-due screenings: Colon from 45 on the USPSTF’s line, ten years after a clean colonoscopy, with a mammogram and the rest by age and history. Polyps, a poor prep or a new family history shorten the ten years. Some acromegaly guidelines move it to five where IGF‑1 isn’t normal, on far higher levels and mixed population data, while the one approved GHRH analogue’s label rules out active malignancy and wants any earlier one inactive with its treatment complete, so the careful call is to screen first.
On one growth-axis protocol, Cycle 3 waited with every lab in range, because a clear colonoscopy’s ten years ran out at 55
He felt well with his blood in range, and his doctor still read the date on a ten-year-old report, because a careful program holds every check to its own clock.
Which checks does each of your protocols run on, and where does your team keep the reason for each?
Request a walkthroughRequest a walkthrough for peptide therapyHHS has opened a US pathway for six peptides, and with it comes the standard a whole research team would hold
That opens access for patients and room for innovation, and the clinics leading this medicine are ready to run it well. What supply chain stands behind the compound, what evidence stands behind the prescription and who keeps watch across the years are a research team’s questions, and iksa carries that team’s work onto one record so your doctors can answer them.
The supply chain
Whichever peptide you prescribe, the compound, the pharmacy and the lot go in your note the day you write it, and Clinical Intelligence quotes them back with the note they came from.
The evidence
Every lab keeps its date and source report, every note its author and date, and Clinical Intelligence answers from that record with the source on each line, so the next prescription starts from this patient’s own course.
Adverse event reporting
Strict adverse event reporting starts with hearing it: an injection-site reaction in one message and a new symptom to a different nurse weeks later mean more read together. A side effect that needs a person reaches one with the patient’s words and its urgency, and each review is kept with who and when. Our vision is one adverse event loop, each event linked to the exposure it followed and counted per patient over time, with a person reviewing it.
A source patients can trust
Patients on these protocols have questions all the time, about a bruise at the site or what a new symptom means, and a general AI argues with the prescription. They need guidance their doctor approved, and a clear path when something needs a person.
The doctor, the nurse and the patient all work from one record of what’s prescribed, what’s been reported and why
The harness works inside the checks the doctor set for each protocol, following those markers and any side effect a patient mentions, and the doctor decides each cycle from that record.
Your doctors ask which lot a patient is on and how each marker moved, and read the source behind every answer
Clinical Intelligence quotes the note or report behind each answer and says so when the record holds nothing, so the compound, pharmacy and lot you wrote come back cited beside the labs and screenings. A referral goes on the plan with a way back to the note, and the reason for each cycle is still there to read years later.
Clinical Intelligence: clinical AI and lab trackingYour nurses work the side effects patients report, in their own words, beside the markers each protocol follows
A side effect that needs her comes to her list with the patient’s words, its urgency and a suggested action, she replies from the card and resolves it, and her review stays on file with who and when. She can open a marker against its reference range and ask Clinical Intelligence where it stands against the line in the doctor’s note, and someone who writes in naming a peptide gets an Agentic CRM draft from your approved answers for your team to approve or change.
Agentic CRM: scheduling and follow-upPatients get guidance their doctor approved, and a clear path when a side effect needs a person
Patient AI answers from the patient’s own record and what their doctor wrote, in plain words, and a question about timing or about adding anything to the plan comes back as the doctor’s call. A bruise at the site or a new symptom starts with safety questions, emergency wording gets an immediate instruction, and anything that needs a person reaches the nurse or the doctor with what the patient reported and a suggested action, and the patient is told who follows up.
Patient AI: the treatment companion
Your cycles, the side effects reported and the reasons you wrote are the real-world evidence this medicine is building
Why each cycle started or waited stays in the note behind it, with each lab still showing its date and source report. De‑identified, with each patient’s consent and an ethics review, those cycles, the side effects reported and the decisions you wrote would be a first look at the heart, metabolic and cancer follow-up this field will need. What a first study of your cycles would need →
For the prescriber running peptide protocols at the top of the field
A patient reports a side effect. What does my team see?
Their words, with urgency.Safety questions come first, and it either settles there or reaches your team with the patient’s words, its urgency, what’s known and a suggested action. The patient is told who follows up, your nurse or doctor replies from the card and resolves it, and the review is kept with who and when. Your note carries it into the record, so the adverse event report your clinic files starts from what they said.
Which compound, pharmacy and lot was he on in Cycle 2?
Your note, quoted.Write them in your note when you prescribe, and Clinical Intelligence gives them back with the note they came from, and tells you if the record holds nothing.
What does the new HHS pathway mean for my program?
A pathway, and a standard.HHS’s draft interim policy, announced in the Federal Register on October 30, 2026, opens a path, “to expand and improve patient access,” to six listed peptides compounded by prescription, and its reported conditions include a valid patient-specific prescription, the bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events. Those are the records a careful program keeps for every compounded peptide it prescribes, and iksa is built for that program.
Patients ask whether their peptide is FDA-approved. What do they hear?
What your plan says.Some peptides are FDA-approved for specific uses, among them a GHRH analogue for abdominal fat in HIV and a melanocortin agonist for hypoactive sexual desire in premenopausal women, another was approved and later discontinued, not for safety or effectiveness reasons (Federal Register, 2013), and others are compounded for one patient on your prescription. Prescribing an approved drug beyond its label is an ordinary part of medicine, your note carries your reasons, and Patient AI explains what you wrote.
Will it tell me which peptide to use, or at what dose?
No, those stay yours.The peptide, the dose and the call for this patient stay with you. iksa works from what you wrote, and Patient AI explains your plan without adding to it.
Whose decision is it to start or hold a cycle?
Yours, in your note.That decision is yours, made in your note. What iksa gives you is the record at the moment you decide, with each reading dated and sourced, and a note it can point back to.
My patients already ask a general AI about their peptides. What changes?
They hear your guidance.A general AI knows nothing of this patient and argues with the prescription, telling them the medicine isn’t approved and shouldn’t be used. Patient AI answers from their record and what you wrote, and what it can’t answer from there comes back to your team. When you ask, Clinical Intelligence answers from that patient’s notes, charts and lab reports, quoted as they’re written, with the source on each line, and tells you if the record holds nothing.
My protocols don’t all need the same checks. Whose list does it use?
Yours, plus any alert.The markers you write into that patient’s plan are the ones it follows, along with any value that raises an alert, so a protocol that never touches the growth axis doesn’t get an IGF‑1 on its list. How long labs stand, which screenings apply and how often they repeat are yours to write down, and the record keeps them beside the note they came from.
A patient brings a report from another practice. Can it go on the record?
It goes on file.Once it’s filed in the chart it goes on the record showing the date of service it prints, or saying no date could be found, and if iksa can’t tell what the file is, it keeps the file and says why. Whether that exam counts as current is what you write in your note, and that’s what the record goes by.
Do I have to move my charts to use this?
No. Keep charting.You go on charting in your EHR and running the calendar from your booking system, and iksa reads what’s charted there, by connection or by upload. The part it takes on is each protocol’s labs and screenings with the reason each cycle started or waited.
Would you call this an OS for peptide therapy, or one more piece of peptide clinic software that tracks vials?
Not a vial tracker.We call it the harness for n‑of‑1 medicine, because each patient’s labs, screenings and side effects, cycle after cycle, are the record this medicine runs on.
What is n‑of‑1 medicine?All practicesiksa beside your EHRProtocol management softwareWhat iksa adds
We’d like to read one of your protocols, from the compound and lot to the checks around it
Bring a protocol you run. We’ll walk one patient through it.